Tue, Oct 21, 2014, 8:42 AM EDT - U.S. Markets open in 48 mins.

Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

  • blackmorongo blackmorongo Apr 10, 2013 10:01 AM Flag

    Failure of Short Telomere Study not accurate portrayal of results - why the negative spin?

    Study Conclusions:

    In the original primary analysis of PFS, imetelstat given as maintenance therapy appeared to prolong
    PFS in patients with advanced NSCLC whose tumors have short telomeres, as measured by a
    retrospective qPCR assay.
     Results for Telo-FISH, a prospective assay, show a trend toward increased PFS benefit in the short
    telomere subgroup.
     Mature OS analyses suggest a survival benefit in patients with both short telomeres and mediumlong
    telomeres. These data are not consistent with the hypothesis that clinical benefit from
    telomerase inhibition is potentially greater in patients with tumors possessing short telomeres.
     The impact of these findings on the development of imetelstat in solid tumors with short telomeres
    is being evaluated.

    Help me with the above - it sounds as though the results were actually better than expected - in other words OS increased for short and medium teliomeres. Please feel free to correct me if I'm misreading this.

    Thx,
    MG

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It baffles me as to why Scarlett_Kelsey and company branded Imetelstat failure for solid tumopr application last fall and caused that massive share-price slide!! I wonder if it was a deliberate action and, hence, a fraud or as Stifel's Klein argues the flawed trials plan by the mangement? What was Kelsey upto when he was privy to all the information when Scarlett openly stated the solid-tumor trials had failled? If I were to hold the power to change the company management, I will fire Scarlett, Kelsey and Huh and bring in more dynamic and mature replacement. None of them really is fit to run Geron. Instead of growing the company, they have managed to shrink it to dangerously low level. They have reduced once well-known outfit to one of the lame oncology research outfit. For what reasons?

    • Nice to see that someone loves me by using a variation of my alias!!!

 
GERN
2.18+0.07(+3.32%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.